PeptiDream (TSE:4587) just logged two meaningful scientific wins, advancing an oral dual IL 17 program into its clinical portfolio and hitting a preclinical siRNA delivery milestone with Alnylam, ...
If you are wondering whether PPL is still a sensible buy at today’s price or if the easy money has already been made, you are not alone. The valuation story is more nuanced than the headline numbers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback